Phase 2
Completed N=80
Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)
Diabetes Mellitus, Non-Insulin-Dependent
Source: ClinicalTrials.gov NCT00758069 ↗
Enrolled (actual)
80
Serious AEs
—
Results posted
Sep 2009
Primary outcomePrimary: Change From Baseline in 24-hour Weighted Mean Plasma Glucose — -34.9; -28.6; -9.0 mg/dL — p=<0.001
Summary
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in 24-hour Weighted Mean Plasma Glucose |
-34.9; -28.6; -9.0 | <0.001 sig |
| SECONDARY Change From Baseline in Plasma Glucose |
-22.3; -16.0; -3.1 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Patients Have Type 2 Diabetes Mellitus On Diet/Exercise Therapy
Exclusion Criteria
- Patients Have Type 1 Diabetes Mellitus
Data sourced from ClinicalTrials.gov (NCT00758069). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.